342 related articles for article (PubMed ID: 32898271)
1. Comparison of A(H3N2) Neutralizing Antibody Responses Elicited by 2018-2019 Season Quadrivalent Influenza Vaccines Derived from Eggs, Cells, and Recombinant Hemagglutinin.
Wang W; Alvarado-Facundo E; Vassell R; Collins L; Colombo RE; Ganesan A; Geaney C; Hrncir D; Lalani T; Markelz AE; Maves RC; McClenathan B; Mende K; Richard SA; Schofield C; Seshadri S; Spooner C; Utz GC; Warkentien TE; Levine M; Coles CL; Burgess TH; Eichelberger M; Weiss CD
Clin Infect Dis; 2021 Dec; 73(11):e4312-e4320. PubMed ID: 32898271
[TBL] [Abstract][Full Text] [Related]
2. Elicitation of Protective Antibodies against 20 Years of Future H3N2 Cocirculating Influenza Virus Variants in Ferrets Preimmune to Historical H3N2 Influenza Viruses.
Allen JD; Jang H; DiNapoli J; Kleanthous H; Ross TM
J Virol; 2019 Feb; 93(3):. PubMed ID: 30429350
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Human H3N2 Antibody Responses Elicited by Egg-Based, Cell-Based, and Recombinant Protein-Based Influenza Vaccines During the 2017-2018 Season.
Gouma S; Zost SJ; Parkhouse K; Branche A; Topham DJ; Cobey S; Hensley SE
Clin Infect Dis; 2020 Sep; 71(6):1447-1453. PubMed ID: 31598646
[TBL] [Abstract][Full Text] [Related]
4. Nucleoside-Modified mRNA-Based Influenza Vaccines Circumvent Problems Associated with H3N2 Vaccine Strain Egg Adaptation.
Gouma S; Furey C; Santos JJS; Parkhouse K; Weirick M; Muramatsu H; Pardi N; Fan SHY; Weissman D; Hensley SE
J Virol; 2023 Jan; 97(1):e0172322. PubMed ID: 36533954
[TBL] [Abstract][Full Text] [Related]
5. Effect of Repeat Vaccination on Immunogenicity of Quadrivalent Cell-Culture and Recombinant Influenza Vaccines Among Healthcare Personnel Aged 18-64 Years: A Randomized, Open-Label Trial.
Gaglani M; Kim SS; Naleway AL; Levine MZ; Edwards L; Murthy K; Dunnigan K; Zunie T; Groom H; Ball S; Jeddy Z; Hunt D; Wesley MG; Sambhara S; Gangappa S; Grant L; Cao W; Gross FL; Mishina M; Fry AM; Thompson MG; Dawood FS; Flannery B
Clin Infect Dis; 2023 Feb; 76(3):e1168-e1176. PubMed ID: 36031405
[TBL] [Abstract][Full Text] [Related]
6. Bivalent H1 and H3 COBRA Recombinant Hemagglutinin Vaccines Elicit Seroprotective Antibodies against H1N1 and H3N2 Influenza Viruses from 2009 to 2019.
Allen JD; Ross TM
J Virol; 2022 Apr; 96(7):e0165221. PubMed ID: 35289635
[TBL] [Abstract][Full Text] [Related]
7. Neutralizing Antibody Responses to Homologous and Heterologous H1 and H3 Influenza A Strains After Vaccination With Inactivated Trivalent Influenza Vaccine Vary With Age and Prior-year Vaccination.
Wang W; Chen Q; Ford-Siltz LA; Katzelnick LC; Parra GI; Song HS; Vassell R; Weiss CD
Clin Infect Dis; 2019 May; 68(12):2067-2078. PubMed ID: 30256912
[TBL] [Abstract][Full Text] [Related]
8. In-depth phylogenetic analysis of the hemagglutinin gene of influenza A(H3N2) viruses circulating during the 2016-2017 season revealed egg-adaptive mutations of vaccine strains.
Galli C; Orsi A; Pariani E; Lai PL; Guarona G; Pellegrinelli L; Ebranati E; Icardi G; Panatto D
Expert Rev Vaccines; 2020 Jan; 19(1):115-122. PubMed ID: 31875483
[No Abstract] [Full Text] [Related]
9. Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains.
Zost SJ; Parkhouse K; Gumina ME; Kim K; Diaz Perez S; Wilson PC; Treanor JJ; Sant AJ; Cobey S; Hensley SE
Proc Natl Acad Sci U S A; 2017 Nov; 114(47):12578-12583. PubMed ID: 29109276
[TBL] [Abstract][Full Text] [Related]
10. A virus-like particle vaccination strategy expands its tolerance to H3N2 antigenic drift by enhancing neutralizing antibodies against hemagglutinin stalk.
Yang JR; Cheng CY; Chen CY; Lin CH; Kuo CY; Huang HY; Wu FT; Yang YC; Wu CY; Liu MT; Hsiao PW
Antiviral Res; 2017 Apr; 140():62-75. PubMed ID: 28093338
[TBL] [Abstract][Full Text] [Related]
11. Computationally Optimized Broadly Reactive Hemagglutinin Elicits Hemagglutination Inhibition Antibodies against a Panel of H3N2 Influenza Virus Cocirculating Variants.
Wong TM; Allen JD; Bebin-Blackwell AG; Carter DM; Alefantis T; DiNapoli J; Kleanthous H; Ross TM
J Virol; 2017 Dec; 91(24):. PubMed ID: 28978710
[TBL] [Abstract][Full Text] [Related]
12. Influenza H3 hemagglutinin vaccine with scrambled immunodominant epitopes elicits antibodies directed toward immunosubdominant head epitopes.
Chiba S; Kong H; Neumann G; Kawaoka Y
mBio; 2023 Aug; 14(4):e0062223. PubMed ID: 37466314
[TBL] [Abstract][Full Text] [Related]
13. Differential Recognition of Computationally Optimized H3 Hemagglutinin Influenza Vaccine Candidates by Human Antibodies.
Abbadi N; Nagashima K; Pena-Briseno A; Ross TM; Mousa JJ
J Virol; 2022 Aug; 96(16):e0089622. PubMed ID: 35916534
[TBL] [Abstract][Full Text] [Related]
14. Novel hemagglutinin nanoparticle influenza vaccine with Matrix-M™ adjuvant induces hemagglutination inhibition, neutralizing, and protective responses in ferrets against homologous and drifted A(H3N2) subtypes.
Smith G; Liu Y; Flyer D; Massare MJ; Zhou B; Patel N; Ellingsworth L; Lewis M; Cummings JF; Glenn G
Vaccine; 2017 Sep; 35(40):5366-5372. PubMed ID: 28844407
[TBL] [Abstract][Full Text] [Related]
15. Mapping of a Novel H3-Specific Broadly Neutralizing Monoclonal Antibody Targeting the Hemagglutinin Globular Head Isolated from an Elite Influenza Virus-Immunized Donor Exhibiting Serological Breadth.
Qiu Y; Stegalkina S; Zhang J; Boudanova E; Park A; Zhou Y; Prabakaran P; Pougatcheva S; Ustyugova IV; Vogel TU; Mundle ST; Oomen R; Delagrave S; Ross TM; Kleanthous H; Qiu H
J Virol; 2020 Feb; 94(6):. PubMed ID: 31826999
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Next-Generation H3 Influenza Vaccines in Ferrets Pre-Immune to Historical H3N2 Viruses.
Allen JD; Ross TM
Front Immunol; 2021; 12():707339. PubMed ID: 34475872
[TBL] [Abstract][Full Text] [Related]
17. Age-specific effects of vaccine egg adaptation and immune priming on A(H3N2) antibody responses following influenza vaccination.
Liu F; Gross FL; Jefferson SN; Holiday C; Bai Y; Wang L; Zhou B; Levine MZ
J Clin Invest; 2021 Apr; 131(8):. PubMed ID: 33690218
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of influenza virus A/H3N2 and B vaccines on the basis of cross-reactivity of postvaccination human serum antibodies against influenza viruses A/H3N2 and B isolated in MDCK cells and embryonated hen eggs.
Kishida N; Fujisaki S; Yokoyama M; Sato H; Saito R; Ikematsu H; Xu H; Takashita E; Tashiro M; Takao S; Yano T; Suga T; Kawakami C; Yamamoto M; Kajiyama K; Saito H; Shimada S; Watanabe S; Aoki S; Taira K; Kon M; Lin JH; Odagiri T
Clin Vaccine Immunol; 2012 Jun; 19(6):897-908. PubMed ID: 22492743
[TBL] [Abstract][Full Text] [Related]
19. Clinical trial to assess immunogenicity of high-dose, adjuvanted, and recombinant influenza vaccines against cell-grown A(H3N2) viruses in adults 65 to 74 years, 2017-2018.
Belongia EA; Levine MZ; Olaiya O; Gross FL; King JP; Flannery B; McLean HQ
Vaccine; 2020 Mar; 38(15):3121-3128. PubMed ID: 32145994
[TBL] [Abstract][Full Text] [Related]
20. Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies.
Kamal RP; Blanchfield K; Belser JA; Music N; Tzeng WP; Holiday C; Burroughs A; Sun X; Maines TR; Levine MZ; York IA
J Virol; 2017 Oct; 91(20):. PubMed ID: 28768855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
